Clinical Trial Update: CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CBA vs FBA conditioning followed by allogeneic HSCT in high-risk and refractory AML is underway; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation | Phase 3 | Status: UNKNOWN